Interestingly, treatment with TMP dose-dependently reduced cMyc and IRF4 at protein as well as mRNA levels (Figures 4A and 4B, respectively), indicating the regulatory role of Sp1 in cMyc and IRF4 expression in MM cells. This evidence concerns the gene IRF4 and Miyoshi myopathy.